The FDA has issued a request for information (RFI) for advancing model-informed drug development (MIDD) to assist CDER and CBER in identifying and prioritizing potential focus areas for future policy ...

ADCT-701 is under clinical development by ADC Therapeutics and currently in Phase I for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According to GlobalData, Phase I drugs for Adrenocortical ...

There is a huge demand therefore for a more informed, balanced approach to decision making and implementation during drug development. Quintiles offers a range of services that can help with this ...

With over 211 antibody-drug ... 13 th World ADC London, Europe’s only discussion and networking forum dedicated to addressing and overcoming the challenges in end-to-end ADC development.

implement rigorous control strategies for superior drug substance quality, develop scalable processes to cut unit operations, accelerate production timelines, and navigate regulatory landscapes with ...

Oberotatug ravtansine is under clinical development by Oxford BioTherapeutics and currently in Phase I for Ovarian Cancer.

The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and ...

The AI model, called TxGNN, is the first one developed specifically to identify drug candidates for rare diseases and conditions with no treatments. It identified drug candidates from existing ...